Search

Displaying results 6761 - 6770 of 7399 in total
  1. Drug

    Rocakinogene sifuplasmid

    go.drugbank.com/drugs/DB16316
    Investigational

    Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma

  2. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  3. Drug

    Debamestrocel

    go.drugbank.com/drugs/DB17934
    Investigational

    Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47266]

  4. Drug

    HMI-203

    go.drugbank.com/drugs/DB18520
    Investigational

    HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc.

  5. Drug

    CDX-6512

    go.drugbank.com/drugs/DB17841
    Experimental

    Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]

  6. Drug

    Cycloleucine

    go.drugbank.com/drugs/DB04620
    Experimental

    Cycloleucine is non-metabolisable amino acid formed by cyclization of leucine. It is also a specific and reversible inhibitor of nucleic acid methylation and widely used in biochemical experiments.

  7. Drug

    Loprazolam

    go.drugbank.com/drugs/DB13643
    Experimental

    Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence and withdrawal symptoms.

  8. Drug

    Dirlotapide

    go.drugbank.com/drugs/DB11399
    InvestigationalVet approved

    It is marketed by Pfizer and Zoetis under the brand name, _Slentrol_, and is not intended for human use.

  9. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  10. Drug

    ChAd-triCoV/Mac

    go.drugbank.com/drugs/DB24997
    Investigational

    ChAd-triCoV/Mac is under investigation in clinical trial NCT06381739 (A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol).